Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy et al. · Journal of Clinical Oncology · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +15

Aspirin Use, Tumor<i>PIK3CA</i>Mutation, and Colorectal-Cancer Survival

Xiaoyun Liao, Paul Lochhead, Reiko Nishihara et al. · New England Journal of Medicine · 2012 · 838 citations · Full text

Medicine, Oncology, Pharmacology +17

HER2 testing in gastric cancer: a practical approach

Josef Rüschoff, Wedad Hanna, Michael Bilous et al. · Modern Pathology · 2012 · 596 citations · Full text

Medicine, Molecular Medicine, Oncology +12

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17